Oura filed to go public on Nasdaq on September 21, 2026, seeking to raise up to $2.2 billion and a fully diluted valuation near $15.6 billion, revealing $1.21 billion in nine-month revenue alongside $924.3 million in net losses.
Aktiia's Hilo Band, the first FDA-cleared cuffless blood pressure wearable, launched nationwide in the U.S. on July 21, 2026, relying on machine learning to turn an optical pulse-wave reading into a blood pressure estimate -- a bet that a decade of algorithm development can replace the cuff.
Sonova's Phonak division launched its Eon hearing aid platform in the U.S. on August 24, 2026, built around a new low-power chip that runs a real-time neural network to separate speech from noise -- and shrank the device by a quarter in the process.
OSF HealthCare has expanded its Rapid AI stroke-detection system to rural Illinois hospitals and OSF St. Joseph Medical Center, giving neurologists over 95% accurate scan reads on their phones — even as the rollout roughly doubles their review workload.
Google began phasing out Google Assistant on Android and Wear OS starting September 4, 2026, automatically routing voice requests to Gemini instead — a switch privacy advocates say trades simple, predictable commands for a data-hungry AI with an 18-month default retention window.
Norway's government is drafting rules that could outlaw facial recognition on unidentified people and restrict camera-enabled wearables like Meta and Snap's smart glasses, citing fears over covert filming in public.
A 135-minute investigation by Gamers Nexus and security researchers alleges LG's webOS TVs capture and store audio even in standby mode; LG says the claims are false and that voice data is only processed after a wake word or button press.
University of Virginia dietitian Sibylle Kranz tested popular AI diet-tracking apps and found calorie counts running 250 to 345 calories too low per meal, with fat underestimated by roughly 30 grams, according to research presented at NUTRITION 2026.
Insilico Medicine has dosed the first patient in GENESIS-IPF-3, a 320-patient Phase III trial of rentosertib, an AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis and the first generative-AI-designed drug to reach a pivotal Phase III study.
Cornelis Networks, an Intel spinoff, raised $205 million to scale up its GPU-agnostic Active Compute Fabric networking technology, positioning itself as an alternative to Nvidia's dominant InfiniBand and NVLink interconnects. The bet reflects growing investor interest in AI cluster networking as a chokepoint separate from the chips themselves.